Maxonis Technology & Product
Our goal is to address the unmet medical needs of individuals suffering from spinal cord injuries (SCIs), peripheral nerve injuries (PNIs), and other nerve traumas
such as traumatic brain injury (TBI).
Our primary focus is on developing and commercializing our patented LPD-916 hydrogel technology, which promotes nerve regeneration.
LDP-916: A Regenerative Peptide–Hydrogel Therapy
A first-in-class technology designed to activate nerve-repair pathways, guide regenerating fibers, and restore meaningful motor and sensory function.
What is LDP-916?
LDP-916 is a bioactive peptide–hydrogel engineered to provide the biological signals and structural support required for regenerating nerves.
The technology integrates targeted peptide sequences with an advanced hydrogel matrix to promote activation, guidance, and restoration across multiple nerve-injury models.
Scientific Foundation
Developed through over 15 years of collaborative research at Tel Aviv University and Tel Aviv Sourasky Medical Center, LDP-916 is supported by extensive biochemical, structural, and in-vivo studies.
LDP-916 is protected by a strong global IP portfolio covering composition, mechanism, and clinical applications.
Preclinical Results
PNI - Peripheral Nerve Injury
Strong recovery across validated medium- and long-gap models
Improved functional outcomes compared with existing repair options
Demonstrated complete motor & sensory recovery in select models
SCI - Spinal Cord Injury
Significant motor improvement across multiple SCI models
Consistent activity in both acute and chronic injuries
Up to 87% of treated animals demonstrated meaningful recovery
Market Opportunity
LDP-916 targets two major nerve-injury segments with significant unmet need and multi-billion-dollar market potential.
Combined addressable opportunity across PNI and SCI: ~$25B
$10.3B
PNI - Peripheral Nerve Injury
$5.5B global market representing extremities (~2.5M surgeries/year). Additional $4.8B adding to all PNI applications
Entry: medium & long gaps (~$3.5B) where unmet need is greatest
Delivered through standard nerve tubes; no workflow change
$14.7B
SCI - Spinal Cord Injury
$14.7B potential across acute and chronic cases
Entry: acute SCI during decompression/stabilization surgery
Expansion into chronic SCI and broader spine procedures
Bridging nerve gaps with nerve regeneration technologies
Preclinical trials demonstrated the ability of the LPD-916 to regenerate severely nerve injuries and bridge nerve gaps.
The LPD-916 technology is the result of 15 years of award-winning collaborative research by Tel Aviv University and Tel Aviv Sourasky Medical Center testing multiple materials and combinations.
LPD-916 has a strong patent portfolio comprised of 5 patent families.
2008
IP provisional - patent #1
2017
Research supported by Baxter, IP provisional - patent #2
2018
IP provisional patent #3
2020
IP provisional - patent #4 + #5
November 2022
Plenty licensed LPD-916 technology from TASMC & TAU
February 2023
Maxonis is the new name. Fund raising of 4M$ completed.
2023 workplan. 2 feasibility studies launched, PNI & SCI
November 2023
Discussions with the FDA & EMA Workplan 2024-2025
January 2024
First successful results in SCI study. 2024 workplan launched
2025
IND Preparation & Submission & foundation for first-in-human trials
2025 Development Pipeline
Maxonis is advancing a robust pipeline of innovative therapies designed to revolutionize nerve regeneration and repair, targeting critical unmet needs in spinal cord, peripheral nerve and traumatic brain injuries.
